Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study

Hypertension

Volumn 41, Issue 4, 2003, Pages 978-983

  Freitag, Michael H ^a,b   Larson, Martin G ^a,e   Levy, Daniel ^a,c,d,e   Benjamin, Emelia J ^a,e   Wang, Thomas J ^a   Leip, Eric P ^a   Wilson, Peter W F ^a,e   Vasan, Ramachandran S ^a,e,f  

^a Heart Lung Blood Institute's Heart   (United States)

^b METROWEST MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f FRAMINGHAM HEART STUDY   (United States)

Author keywords

Blood pressure; Epidemiology; Hemodynamics; Hypertension, essential; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SEX DIFFERENCE;

BLOOD PRESSURE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 0037386794     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000061116.20490.8D     Document Type: Article

References (37)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
2. Melo LG, Pang SC, Ackermann U. Atrial natriuretic peptide: regulator of chronic arterial blood pressure. News Physiol Sci. 2000;15:143-149.
3. Hirata Y, Matsumoto A, Aoyagi T, Yamaoki K, Komuro I, Suzuki T, Ashida T, Sugiyama T, Hada Y, Kuwajima I, Nishinaga M, Akioka H, Nakajima O, Nagai R, Yazaki Y. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res. 2001;51:585-591.
4. Dessi-Fulgheri P, Sarzani R, Rappelli A. The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J Nephrol. 1998;11:296-299.
5. Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, Eid H, Scholkens BA, de Bold AJ. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation. 1996;93:2059-2067.
6. Rubattu S, Volpe M. The atrial natriuretic peptide: a changing view. J Hypertens. 2001;19:1923-1931.
7. Marttila M, Hautala N, Paradis P, Toth M, Vuolteenaho O, Nemer M, Ruskoaho H. GATA4 mediates activation of the B-type natriuretic peptide gene expression in response to hemodynamic stress. Endocrinology. 2001;142:4693-4700.
8. Kuroski de Bold ML. Atrial natriuretic factor and brain natriuretic peptide gene expression in the spontaneous hypertensive rat during postnatal development. Am J Hypertens. 1998;11:1006-1018.
9. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci. 1998;95:519-529.
10. Buckley MG, Markandu ND, Miller MA, Sagnella GA, MacGregor GA. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hypertens. 1993;7:245-250.
11. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, Tahara A, Toda I, Takeuchi K, Kurihara N. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 1992;92:29-34.
12. Nakamura T, Ichikawa S, Sakamaki T, Fujie M, Yagi A, Kurashina T, Murata K. Plasma levels of atrial natriuretic peptide in patients with borderline and essential hypertension. Tohoku J Exp Med. 1988;154:205-213.
13. Wambach G, Gotz S, Suckau G, Bonner G, Kaufmann W. Plasma levels of atrial natriuretic peptide are raised in essential hypertension during low and high sodium intake. Klin Wochenschr. 1987;65:232-237.
14. Montorsi P, Tonolo G, Polonia J, Hepburn D, Richards AM. Correlates of plasma atrial natriuretic factor in health and hypertension. Hypertension. 1987;10:570-576.
15. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension. 1996;28:22-30.
16. Lund-Johansen P. The haemodynamic pattern in mild and borderline hypertension. Acta Med Scand Suppl. 1983;686:15-21.
17. Liao D, Arnett DK, Tyroler HA, Riley WA, Chambless LE, Szklo M, Heiss G. Arterial stiffness and the development of hypertension: the ARIC Study. Hypertension. 1999;34:201-206.
18. Mourlon-Le Grand MC, Poitevin P, Benessiano J, Duriez M, Michel JB, Levy BI. Effect of a nonhypotensive long-term infusion of ANP on the mechanical and structural properties of the arterial wall in Wistar-Kyoto and spontaneously hypertensive rats. Arterioscler Thromb. 1993;13:640-650.
19. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Simari RD, John C. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol. 2000;35:796-801.
20. Mitchell GF, Izzo JL Jr, Lacourciere Y, Ouellet JP, Neutel J, Qian C, Kerwin LJ, Block AJ, Pfeffer MA. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the Conduit Hemodynamics of Omapatrilat International Research Study. Circulation. 2002;105:2955-2961.
21. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham offspring study. Am J Epidemiol. 1979;110:281-290.
22. Sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
23. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee J Hypertens. 1999;17:151-183.
24. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
25. Wang T, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PWF, Sutherland P, Omland T, Vasan RS. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90:254-258.
26. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682-1686.
27. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension: the Framingham Heart Study. Circulation. 1994;90:179-185.
28. Iso H, Kiyama M, Doi M, Nakanishi N, Kitamura A, Naito Y, Sato S, Iida M, Konishi M, Shimamoto T. Left ventricular mass and subsequent blood pressure changes among middle-aged men in rural and urban Japanese populations. Circulation. 1994;89:1717-1724.
29. SAS/STAT User's Guide. Version 8. Cary, NC: SAS Institute Inc; 1999.
30. Talartschik J, Eisenhauer T, Schrader J, Schoel G, Buhr-Schinner H, Scheler F. Low atrial natriuretic peptide plasma concentrations in 100 patients with essential hypertension. Am J Hypertens. 1990;3:45-47.
31. Flickinger AL, Burnett JC Jr, Turner ST. Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc. 1995;70:932-938.
32. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic pcptide and salt-sensitive hypertension. Science. 1995;267:679-681.
33. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:65-68.
34. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16:301-307.
35. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab. 1996;81:3871-3876.
36. Magga J, Vuolteenaho O, Marttila M, Ruskoaho H. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro. Circulation. 1997;96:3053-3062.
37. Luchner A, Brockel U, Muscholl M, Hense HW, Doring A, Riegger GA, Schunkert H. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res. 2002;53:720-727.